Aberdeen Group plc Purchases Shares of 51,243 Palvella Therapeutics, Inc. $PVLA

Aberdeen Group plc acquired a new stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 51,243 shares of the company’s stock, valued at approximately $3,212,000.

Several other large investors also recently made changes to their positions in PVLA. Federated Hermes Inc. bought a new stake in Palvella Therapeutics in the 3rd quarter valued at about $21,255,000. Millennium Management LLC bought a new position in Palvella Therapeutics in the first quarter worth approximately $7,553,000. Geode Capital Management LLC grew its stake in Palvella Therapeutics by 84.7% in the second quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock valued at $3,923,000 after acquiring an additional 79,787 shares during the period. Frazier Life Sciences Management L.P. increased its holdings in shares of Palvella Therapeutics by 4.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock valued at $16,283,000 after acquiring an additional 32,388 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Palvella Therapeutics during the first quarter valued at approximately $533,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 20.50% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on PVLA. TD Cowen reissued a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. Cantor Fitzgerald raised their price objective on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Craig Hallum began coverage on shares of Palvella Therapeutics in a report on Thursday, December 4th. They set a “buy” rating and a $175.00 price objective for the company. HC Wainwright set a $200.00 target price on shares of Palvella Therapeutics and gave the stock a “buy” rating in a research report on Monday, December 15th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Palvella Therapeutics in a report on Monday, December 29th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $158.69.

Palvella Therapeutics Stock Performance

NASDAQ:PVLA opened at $85.66 on Friday. Palvella Therapeutics, Inc. has a 52 week low of $18.05 and a 52 week high of $114.69. The firm has a 50-day moving average price of $91.60 and a two-hundred day moving average price of $77.06. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -32.57 and a beta of -0.16.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.